Keywords: EMA, Registration fees, SMEs, Orphan drugs

EMA updates on fee reduction for SMEs developing orphan drugs in 2013

Article | 19 December 2012

The European Medicines Agency’s policy on fee reductions for orphan medicinal products is set to continue into 2013. The ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in